Predictive value &changes in Child-Pugh score in chronic hepatitis C cirrhotic patients treated with Direct Acting Antiviral agents | ||||
| Egyptian Journal of Medical Research | ||||
| Article 6, Volume 1, Issue 2, June 2020, Page 61-74 PDF (817.42 K) | ||||
| Document Type: Original Article | ||||
| DOI: 10.21608/ejmr.2020.90107 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
| Basel Abdelmonem Ebeid1; Alaa Aboud Muhammed1; Shaimaa Ali Abd Elkareem2; Asmaa Soliman* 1 | ||||
| 1Tropical Medicine department, Faculty of Medicine, Beni-Suef University, Egypt | ||||
| 2Clinical Pathology department, Faculty of Medicine, Beni-Suef University, Egypt | ||||
| Abstract | ||||
| Background: Hepatitis C is a worldwide problem with a prevalence estimated to be 3 % according to the World Health Organization (WHO) about 130-150 million people worldwide are chronically infected with hepatitis C virus (HCV). Egypt has the highest prevalence of HCV estimated to be 7.3% with predominance of genotype 4. Direct -acting antiviral agents (DAAs) are highly effective and well tolerated in patients with chronic hepatitis C virus infection, including those with compensated cirrhosis. The availability of antiviral agents, which can be administered in short, interferon (IFN)‐free regimens, has improved the management of patients with HCV infection dramatically. Clinical studies have demonstrated rates of sustained virologic response (SVR) of over 90% with these regimens, even in patients with compensated cirrhosis. Aim: The aim was to assess the clinical impact of direct-acting antiviral treatment in patients with compensated hepatitis C virus-related cirrhosis after one year of follow-up. Methods: An observational prospective study was conducted on 100 patients with compensated cirrhosis treated in 2017, analyzing the evolution of liver function and the development of hepatocellular carcinoma and clinical decompensation. Results: Most patients were males (60%), the mean age was 57.3±6.1years. All participants were Child-Pugh A class at the start of the treatment. SVR 12 was achieved in all patients (100%). Eight patients suffered clinical decompensation, three( 3.3%) of them changed to Child B and five (5.5%) patients changed to Child C. The incidence of de novo hepatocellular carcinoma during the follow-up was (4 %). There was a significant improvement in the mean platelets count, AST, ALT (P < 0.001) after treatment and the mean albumin level decreased but still in the normal range. Conclusion: Treatment with Direct-acting antiviral was assosciated with high rates of SVR, but not associated in the short term with a decrease in the development of hepatic decompensation or hepatocellular carcinoma compared to what it was reported for untreated compensated cirrhotic patients. | ||||
|
Statistics Article View: 239 PDF Download: 431 |
||||
